首页

Daewoong Pharmaceutical Co.,Ltd sell "ENVLO®"

基本信息

994
59
25
4.5(44)

子类别与细分类别

交易类型

出售

产品名称

ENVLO®

详情

规格参数

  • CAS Number: 1415472-28-4
  • Chemical Formula: C24H27ClO6
  • 适应症: SGLT2抑制剂,用于治疗2型糖尿病,可单药使用或与其他降糖药联合使用
  • IUPAC Name: (2S,3R,4R,5S,6R)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
  • EC Number:
  • Molecular Weight: 446.9
  • 监管批准状态: 于2022年获得韩国食品药品安全部(MFDS)批准,并于2023年5月在韩国上市
  • 剂型: 口服片剂,符合SGLT2抑制剂类药物的标准剂型

其他信息

补充描述:

Envlo (enavogliflozin) is a best-in-class SGLT2 inhibitor for type 2 diabetes, launched in Korea in May 2023 after MFDS approval in 2022. Its Phase III program in Korea covered both monotherapy and combination use (dual and triple therapy) with other anti-diabetic drugs, and a Phase II obesity trial as combination therapy is planned in Korea. It offers the smallest tablet size among potent, novel SGLT2 inhibitors while delivering superior glucose control and a longer duration of action, with confirmed in vivo efficacy in the STAM mouse NASH model and the TAA-induced mouse liver fibrosis model. The compound is being developed as an asset targeting multiple indications for both human and veterinary use.
筛选:
排序方式:

    暂无评论。

匹配的产品和服务

基于贸易类型、类别、规格和价格范围的B2B匹配

相似产品和服务

与您正在查看的内容相关的产品和服务

其他人也浏览了

查看过此产品的人也浏览了其他产品和服务